Truist raised the firm’s price target on Globus Medical (GMED) to $105 from $93 and keeps a Buy rating on the shares. The firm cites multiple expansion in the comp group for the price target update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Globus Medical’s Earnings Call Highlights Robust Growth
- Globus Medical rises 33.2%
- Midday Fly By: Musk pay plan approved, ‘GTA VI’ delayed
- Globus Medical price target raised to $92 from $88 at RBC Capital
- Globus Medical: Strong Q3 Performance and Raised Guidance, But Long-term Growth Concerns Justify Hold Rating